RVTY · Revvity, Inc.

$115.02 +3.63 (+3.26%) At close · Aug 5

Market Cap

$12.85B

111.56M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$2.86B +3.7%

FY2025

Net Income

$241.2M -10.8%

FY2025

Gross Margin

60.08% -3.5pp

FY2022

Operating Margin

12.49% -0.1pp

FY2025

Diluted EPS

$2.07 -5.9%

FY2025

Operating Cash Flow

$582.93M -7.2%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	-4.8%	-5.5%	+3.1%	$2.83B – $2.86B	$2.9B	$2.86B	$2.76B	$2.75B	$3.31B	$3.83B	$3.78B	$2.88B	$2.78B	$2.26B	$2.12B	$2.1B	$2.24B	$2.16B	$2.12B	$1.92B	$1.7B	$1.55B	$1.66B
Cost of Revenue	+27.3%	+12.9%	+4.5%	—	—	—	—	—	—	—	—	—	$1.44B	$708.69M	$664.8M	$696.46M	$708.02M	$783.58M	$762.99M	$686.81M	$945.72M	$851.78M	$925.97M
Gross Profit	+12.5%	+13.1%	+7.5%	—	—	—	—	—	$1.99B	$2.43B	$2.11B	$1.4B	$1.34B	$1.07B	$1.01B	$964.23M	$1B	$976.14M	$963.21M	$847.8M	$761.23M	—	—
Gross Margin	—	—	—	—	—	—	—	—	60.08%	63.59%	55.78%	48.41%	48.27%	47.57%	47.9%	45.81%	44.9%	45.24%	45.54%	44.19%	44.66%	—	—
Research & Development	-0.9%	+8.1%	+6.7%	—	$220.13M	$215.84M	$196.84M	$216.58M	$221.62M	$200.34M	$146.44M	$189.34M	$194M	$139.46M	$124.18M	$112.54M	$108.06M	$132.4M	$131.84M	$115.82M	$94.81M	$90.49M	$93.03M
Selling, General & Administrative	-1.1%	+6.7%	+5.4%	—	$996.05M	$991.89M	$994.07M	$1.02B	$1.03B	$975.19M	$716.47M	$815.32M	$811.91M	$626.02M	$590.47M	$587.22M	$648.21M	$581.9M	$627.37M	$624.39M	$487.31M	$476.82M	$486.37M
Amortization of Intangibles	-3.3%	+15.8%	+15.9%	—	$338M	$335.6M	$359.4M	$365.1M	$370.6M	$256.6M	$161M	$164.3M	$135.9M	$73.7M	$71.5M	$76.6M	$81.4M	$89.3M	$90.1M	$80M	$60.7M	—	—
Depreciation & Amortization	-1.7%	+15.0%	+14.4%	—	—	$405.34M	$427.85M	$431.77M	$427M	$311.44M	$201.65M	$214.03M	$180.59M	$105M	$99.97M	$105.36M	$110.47M	$126.88M	$125.13M	$110.92M	$89.16M	$80.76M	$77.38M
Restructuring Charges	—	-9.9%	+2.8%	—	—	—	$17.5M	$26.6M	$13.6M	-$14.36M	$7.66M	$29.43M	$11.14M	$12.66M	$5.12M	$13.55M	$13.33M	$33.89M	$25.05M	$13.45M	$18.96M	$17.99M	$6.67M
Operating Income	-21.7%	-16.3%	+3.6%	—	$360.29M	$356.64M	$346.74M	$300.56M	$742.7M	$1.26B	$867.27M	$361.97M	$323.88M	$295.62M	$294.58M	$250.93M	$165.01M	$227.79M	$103.12M	$91.13M	$157.57M	$115.95M	$147.63M
Operating Margin	—	—	—	—	—	12.49%	12.59%	10.93%	22.43%	32.88%	22.93%	12.55%	11.66%	13.1%	13.92%	11.92%	7.38%	10.56%	4.88%	4.75%	9.25%	7.48%	8.89%
EBITDA	-13.3%	-6.5%	+7.9%	—	—	$761.98M	$774.59M	$732.33M	$1.17B	$1.57B	$1.07B	$576M	$504.47M	$400.62M	$394.55M	$356.29M	$275.47M	$354.67M	$228.25M	$202.05M	$246.73M	$196.71M	$225M
Interest Expense	-3.9%	+13.1%	+9.3%	—	$93.94M	$92.19M	$96.28M	$98.81M	$103.96M	—	$49.71M	$63.63M	$66.98M	$43.94M	$41.53M	$38M	$36.27M	$49.92M	$45.79M	$24.78M	$15.89M	$16.01M	—
Interest Income	+105.4%	+98.5%	+46.7%	—	$27.33M	$31.1M	$73.19M	$72.13M	$3.59M	$2.24M	$1.01M	$1.5M	$1.14M	$2.57M	$702K	$673K	$667K	$650K	$747K	$1.88M	$832K	$1.04M	—
Other Non-Operating Income	—	—	—	—	-$94.4M	-$88.36M	-$30.62M	-$117.59M	-$90.86M	-$54.88M	-$67.2M	-$124.83M	-$66.2M	$1.1M	-$50.51M	-$42.12M	-$41.14M	-$64.11M	-$47.96M	-$26.77M	$8.38M	-$15.79M	—
Pretax Income	-25.6%	-19.6%	+2.5%	—	$265.89M	$268.28M	$316.13M	$182.98M	$651.84M	$1.2B	$800.07M	$237.14M	$257.68M	$296.72M	$244.07M	$208.81M	$123.87M	$163.68M	$55.16M	$64.35M	$165.95M	$100.16M	$103.59M
Income Tax	-41.1%	-30.0%	+3.6%	—	$26.78M	$28.39M	$33.06M	$3.47M	$139.16M	$314.15M	$169.51M	$9.39M	$20.21M	$139.83M	$28.36M	$20.02M	-$6.27M	-$10.58M	-$16.13M	$63.18M	$27.04M	$26.7M	$12.7M
Net Income	-24.9%	-19.8%	+1.3%	—	$239.68M	$241.2M	$270.39M	$693.09M	$569.18M	$943.16M	$727.89M	$227.56M	$237.93M	$292.63M	$234.3M	$212.43M	$157.78M	$167.21M	$69.94M	$7.66M	$390.98M	$82.08M	$126.41M
Net Margin	—	—	—	—	—	8.45%	9.81%	25.2%	17.19%	24.64%	19.24%	7.89%	8.56%	12.97%	11.08%	10.09%	7.05%	7.75%	3.31%	0.4%	22.94%	5.29%	7.62%
Comprehensive Income	+13.4%	-14.3%	+11.4%	—	$302.58M	$415.17M	$150.97M	$863.9M	$284.37M	$812.43M	$895.57M	$204.39M	$107.96M	$346.98M	$179.39M	$141.67M	$104.99M	$178.21M	$82.45M	$10.71M	$357.54M	$88.15M	—
EPS (Basic) USD/shares	-22.9%	-20.5%	+0.9%	—	—	$2.07	$2.21	$5.56	$4.51	$8.12	$6.52	$2.06	$2.15	$2.67	$2.14	$1.89	$1.40	$1.49	$0.61	$0.07	$3.34	$0.71	$1.07
EPS (Diluted) USD/shares	-22.8%	-20.4%	+1.0%	$5.30 – $5.40*	—	$2.07^G	$2.20^G	$5.55	$4.50	$8.08	$6.49	$2.04	$2.13	$2.64	$2.12	$1.87	$1.39	$1.47	$0.61	$0.07	$3.31	$0.70	$1.07
Shares Outstanding (Basic Avg) shares	-2.6%	+0.9%	+0.4%	—	—	116.54M	122.76M	124.7M	126.16M	116.17M	111.51M	110.83M	110.56M	109.86M	109.48M	112.51M	112.59M	112.25M	113.73M	112.98M	117.11M	116.25M	—
Shares Outstanding (Diluted Avg) shares	-2.7%	+0.8%	+0.3%	—	—	116.6M	122.82M	124.81M	126.43M	116.67M	112.09M	111.5M	111.53M	110.86M	110.31M	113.32M	113.74M	113.5M	114.86M	113.86M	117.98M	116.59M	—

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2025: $2.5B in buybacks, $582.1M in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

5.24×

Peer median 4.88×

EV/EBIT

42.19×

Peer median 27.96×

P/E (TTM)

55.39×

Peer median 32.46×

Peer medians compare against the 24 similar-size Diagnostics & Research companies (of 48 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Life Sciences	$1,431,104,000	$1,398,601,000	$1,458,192,000	$1,292,909,000	—	—	—	—
Diagnostics	$1,424,947,000	$1,356,425,000	$1,292,379,000	$2,018,913,000	—	—	—	—
Diagnostics	—	—	—	—	$2,931,939,000	$2,066,942,000	$1,137,512,000	$1,084,785,000
Discovery Analytical Solutions	—	—	—	—	—	$596,288,000	$1,746,161,000	$1,693,211,000
Life Sciences	—	—	—	—	$895,869,000	—	—	—

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total International	$1,729,777,000	$1,657,170,000	$1,632,917,000	$1,765,302,000	—	—	—	—
Americas	$1,255,961,000	$1,223,087,000	$1,215,613,000	$1,662,643,000	$1,806,672,000	$1,036,995,000	$1,118,796,000	$1,065,122,000
United States	$1,126,274,000	$1,097,856,000	$1,117,654,000	$1,546,520,000	$1,682,294,000	$921,574,000	$974,187,000	$906,398,000
Other International	$1,000,204,000	$931,705,000	$859,902,000	$1,152,919,000	—	—	—	—
Europe	$824,978,000	$742,614,000	$747,023,000	$831,811,000	$1,216,810,000	$1,021,964,000	$787,378,000	$778,092,000
Asia	$775,112,000	$789,325,000	$787,935,000	$817,368,000	$804,326,000	$604,271,000	$977,499,000	$934,782,000
China	$425,060,000	$450,007,000	$454,426,000	$476,366,000	$449,588,000	$305,660,000	$581,688,000	$559,865,000
Germany	$177,664,000	$162,575,000	$193,170,000	—	—	$200,294,000	$146,577,000	$142,411,000
United Kingdom	$126,849,000	$112,883,000	$125,419,000	$136,017,000	$357,911,000	$323,837,000	$70,703,000	$72,124,000
France	—	—	—	—	—	$148,898,000	$96,994,000	$97,990,000
India	—	—	—	—	—	$103,785,000	$97,423,000	$92,327,000
Italy	—	—	—	—	—	$163,056,000	$101,461,000	$95,908,000
Japan	—	—	—	—	—	$88,473,000	$82,478,000	$79,238,000
South Korea	—	—	—	—	—	$114,846,000	$71,069,000	$60,126,000
Other International	—	—	$1,053,072,000	$1,152,919,000	$1,338,015,000	$1,112,159,000	$1,257,095,000	$671,609,000
Total International	—	—	$1,632,917,000	$1,765,302,000	$2,145,514,000	$1,741,656,000	$1,909,486,000	$1,871,598,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Product	$2,389,984,000	$2,338,211,000	$2,415,893,000	$2,634,582,000	$2,735,068,000	$2,280,853,000	$2,017,042,000	$1,935,493,000
Service	$466,067,000	$416,815,000	$334,678,000	$677,240,000	$1,092,740,000	$382,377,000	$866,631,000	$842,503,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2021	FY2020	FY2019	FY2018	FY2017
Diagnostics	$1,219,944,000	$874,206,000	$189,330,000	$153,196,000	$146,862,000
Discovery Analytical Solutions	$189,798,000	$183,471,000	$238,331,000	$230,481,000	$205,259,000
Corporate	-$77,364,000	-$79,096,000	-$65,688,000	-$59,793,000	-$56,506,000

Operating Margin by Segment (%)

Component	FY2021	FY2020	FY2019	FY2018
Diagnostics	41.6%	42.3%	16.6%	14.1%
Discovery Analytical Solutions	—	30.8%	13.6%	13.6%

Key facts CIK 31791 CUSIP 714046109 13F (30d) 248 filings 223 filers Visit website Investor relations